Sath Shukla Sells 14,800 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 14,800 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $1.32, for a total value of $19,536.00. Following the completion of the sale, the chief executive officer now directly owns 1,161,207 shares of the company’s stock, valued at $1,532,793.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sath Shukla also recently made the following trade(s):

• On Monday, August 5th, Sath Shukla sold 17,641 shares of Spero Therapeutics stock. The shares were sold at an average price of $1.31, for a total transaction of $23,109.71.

Spero Therapeutics Stock Performance

Spero Therapeutics stock traded down $0.07 during trading hours on Tuesday, reaching $1.27. 323,154 shares of the stock were exchanged, compared to its average volume of 222,742. Spero Therapeutics, Inc. has a 52-week low of $0.99 and a 52-week high of $1.89. The stock has a market cap of $68.57 million, a P/E ratio of 2.95 and a beta of 0.63. The firm’s 50 day moving average is $1.38 and its 200 day moving average is $1.51.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. The firm had revenue of $10.20 million during the quarter, compared to analysts’ expectations of $9.80 million. During the same period in the prior year, the company posted ($0.23) earnings per share. Equities research analysts expect that Spero Therapeutics, Inc. will post -1.27 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on SPRO shares. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Spero Therapeutics in a research report on Tuesday. TD Cowen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday.

Hedge Funds Weigh In On Spero Therapeutics

Large investors have recently modified their holdings of the business. ADAR1 Capital Management LLC acquired a new position in Spero Therapeutics during the fourth quarter worth about $1,570,000. Vanguard Group Inc. boosted its stake in shares of Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after acquiring an additional 9,675 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after acquiring an additional 418,742 shares during the period. Murchinson Ltd. increased its stake in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Spero Therapeutics during the first quarter worth $31,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.